Price$7.42+0.12 (+1.57%)
01:30 PM07:45 PM
News · 26 weeks54+100%
2025-11-022026-04-26
Mix2490d
- Insider13(54%)
- Other5(21%)
- SEC Filings4(17%)
- Earnings2(8%)
Latest news
25 items- SECSEC Form PRE 14A filed by CorMedix Inc.PRE 14A - CorMedix Inc. (0001410098) (Filer)
- PRCorMedix to Participate in Needham Virtual Healthcare ConferencePARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming 25th Annual Needham Virtual Healthcare Conference taking place April 13 – 16, 2026. 25th Annual Needham Virtual Healthcare ConferenceDate: April 14, 2026Time: 3:00pm EasternFormat: Fireside ChatWebcast: Link to webcast About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic produ
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CorMedix Inc.SCHEDULE 13G/A - CorMedix Inc. (0001410098) (Subject)
- SECCorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- SECSEC Form 10-K filed by CorMedix Inc.10-K - CorMedix Inc. (0001410098) (Filer)
- SECCorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CorMedix Inc. (0001410098) (Filer)
- PRCorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu
- PRCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @ 8:30am ETDomestic: 1-844-676-2922International: 1-412-634-6840Webcast: Webcast Link About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializi
- PRCorMedix to Participate in Upcoming Investor ConferencesBERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March. Leerink Partners Global Healthcare ConferenceDate: March 10, 2026Time: 1:00pm EasternFormat: Fireside ChatWebcast: Link to webcast Citizens Life Sciences ConferenceDate: March 11, 2026Time: 9:35am EasternFormat: Fireside ChatWebcast: Link to webcast Barclays 28th Annual Global Healthcare ConferenceDate: Marc
- INSIDERChief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Executive Officer Todisco Joseph was granted 77,156 shares, increasing direct ownership by 11% to 774,749 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Operating Officer Hurlburt Elizabeth was granted 36,006 shares, increasing direct ownership by 15% to 278,539 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- PRCorMedix Therapeutics Announces Share Repurchase ProgramBERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock. The repurchase program is authorized through December 31, 2027. "With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth s
- PRCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. The Company will share background and updates across its portfolio and pipeline, and outline the business' key growth drivers and upcoming milestones. The event will feature key opinion leaders who will join members of the Company's senior management team, offering insights into evolving
- INSIDERChief Financial Officer Blum Susan was granted 72,820 shares and covered exercise/tax liability with 9,767 shares, increasing direct ownership by 90% to 132,739 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Legal Officer Zelnick Kaufman Beth was granted 72,820 shares and covered exercise/tax liability with 8,803 shares, increasing direct ownership by 38% to 233,102 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Operating Officer Hurlburt Elizabeth was granted 93,010 shares and covered exercise/tax liability with 10,778 shares, increasing direct ownership by 51% to 242,533 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERChief Executive Officer Todisco Joseph was granted 225,900 shares and covered exercise/tax liability with 27,306 shares, increasing direct ownership by 40% to 697,593 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Kaplan Myron was granted 30,453 shares, increasing direct ownership by 15% to 231,487 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Lefkowitz Steven W was granted 30,453 shares, increasing direct ownership by 32% to 125,951 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Dunton Alan W was granted 30,453 shares, increasing direct ownership by 76% to 70,703 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Dillione Janet was granted 30,453 shares, increasing direct ownership by 79% to 68,926 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Duncan Gregory Scott was granted 30,453 shares, increasing direct ownership by 79% to 68,786 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Stewart Robert A was granted 30,453 shares, increasing direct ownership by 85% to 66,453 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)
- INSIDERDirector Dillione Janet sold $68,800 worth of shares (10,000 units at $6.88), decreasing direct ownership by 21% to 38,473 units (SEC Form 4)4 - CorMedix Inc. (0001410098) (Issuer)